Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:33 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE
NCT05172115 · Rajaie Cardiovascular Medical and Research Center · PHASE3 · terminated · last registry update 2021-12-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to the COVID-19 pandemic” | – | Registry record, Rajaie Cardiovascular Medical and Research Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SERPINC1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-12-22Phase 3 first posted: Sanofi, Fitusiran + Clotting factor concentrates (CFC) or bypassing agents (BPA) (NCT05662319)
- 2022-12-21Phase 3 first posted: Jocelyn Fitzgerald, Multimodal Bundle Drugs + Bladder Instillation (NCT05658874)
- 2022-11-23Phase 3 first posted: Galician Research Group on Digestive Tumors, Tinzaparin (NCT05625932)
- 2022-07-15Results posted on the registry: Janssen Research & Development, LLC, JNJ-70033093 25 mg + JNJ-70033093 50 mg (NCT03891524)
- 2022-04-01Phase 3 first posted: University Health Network, Toronto, Ketamine (NCT05306899)
- 2022-02-22Phase 3 first posted: Mario Negri Institute for Pharmacological Research, Recommended treatment schedule + Usual care (NCT05249790)
- 2022-02-07Phase 3 first posted: Medical University of Vienna, Argatroban + Unfractionated heparin (NCT05226442)
- 2022-01-24Phase 3 first posted: Murdoch Childrens Research Institute, unfractionated heparin + 0.9%sodium chloride (NCT05204550)
- 2021-12-28Phase 3 first posted: Anthos Therapeutics, Inc., Abelacimab + Dalteparin (NCT05171075)
- 2021-12-28Phase 3 first posted: Anthos Therapeutics, Inc., Abelacimab + Apixaban (NCT05171049)
- 2021-09-05Phase 3 first posted: Oslo University Hospital, Acetylsalicylic acid + Apixaban (NCT05035277)
- 2021-08-31Results posted on the registry: CorMedix Therapeutics, Neutrolin + Heparin (NCT02651428)
- 2021-06-11Phase 3 first posted: Yale University, Enoxaparin (NCT04924322)
- 2021-02-21Phase 3 first posted: Centro Hospitalar de Lisboa Central, subcutaneous Enoxaparin (NCT04762992)
- 2021-01-14Phase 3 first posted: Cellphire Therapeutics, Inc., Human platelets (NCT04709705)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision